Background Similar to most chronic diseases, Alzheimer's disease (AD) develops slowly
from a preclinical phase into a fully expressed clinical syndrome. We aimed to use …

Background Improved understanding is needed of risk factors and markers of disease
progression in preclinical Alzheimer's disease. We assessed associations between brain β …

Background The biomarker model of Alzheimer's disease postulates a dynamic sequence of
amyloidosis, neurodegeneration, and cognitive decline as an individual progresses from …

Summary Background As preclinical Alzheimer's disease becomes a target for therapeutic
intervention, the overlap between imaging abnormalities associated with typical ageing and …

Summary Background Models of Alzheimer's disease propose a sequence of amyloid β (Aβ)
accumulation, hypometabolism, and structural decline that precedes the onset of clinical …

Currently available evidence strongly supports the position that the initiating event in
Alzheimer's disease (AD) is related to abnormal processing of β-amyloid (Aβ) peptide …

Background Serial MRI scanning of autosomal dominant mutation carriers for Alzheimer's
disease provides an opportunity to track changes that could predate symptoms or clinical …

For decades, the hypothesis that brain deposition of the amyloid β protein initiates
Alzheimer's disease has dominated research and clinical trials. Targeting amyloid β is …

The extent to which cerebral atrophy in Alzheimer's disease changes with time is unknown.
We used multiple MRI scans to measure progression of cerebral atrophy in 12 patients with …

Background In a 2014 cross-sectional analysis, we showed that amyloid and
neurodegeneration biomarker states in participants with no clinical impairment varied …